Amylyx Pharmaceuticals, Inc. Ratios

Ratios Dec2020 Dec2021 Dec2022 Dec2023 Dec2024
Profitability
Gross Margin 88.96%94.10%94.79%
EBT Margin -1,249.25%-30,852.98%-733.12%12.59%-264.42%
EBIT Margin -1,327.60%-29,013.33%-742.85%8.99%-275.44%
EBITDA Margin -1,327.60%-29,013.33%-742.85%8.99%-275.44%
Operating Margin -1,327.60%-29,013.33%-742.85%8.99%-275.44%
Net Margin -1,249.25%-30,852.98%-735.97%11.37%-263.74%
FCF Margin -1,249.05%-26,369.12%-672.95%2.48%-146.86%
Efficiency
Inventory Average 24.05M
Assets Average 248.53M454.45M355.54M
Equity Average 94.72M387.02M299.10M
Invested Capital -151.17M340.61M433.43M164.76M
Asset Utilization Ratio 0.110.950.32
Leverage & Solvency
Interest Coverage Ratio 17.05
Equity Ratio -1.430.870.840.85
Times Interest Earned 17.05
Valuation
Enterprise Value 647.44M2,101.22M622.50M82.61M
Market Capitalization 743.55M2,448.17M993.86M259.11M
Return Ratios
Return on Sales -12.49%-308.53%-7.36%0.11%-2.64%
Return on Capital Employed -1.00%0.10%-0.96%
Return on Invested Capital 0.09%-1.05%
Return on Assets -0.80%0.11%-0.85%
Return on Equity -2.11%0.13%-1.01%